Mirrors of Medicine
@mirrorsmed
Open, multidisciplinary platform facilitating access to unique #CME programmes w/ focus on improving clinical decision making. Both online & offline.
Metabolic adaptations of brain metastasis buff.ly/WrODPJg Brain🧠 metastases present a significant clinical challenge due to their high mortality and limited treatment options, driven by complex and dynamic metabolic adaptations that allow tumor cells to survive and…
Metformin for patients with metastatic #ProstateCancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol out on Lancet Oncology sciencedirect.com/science/articl… In the STAMPEDE phase 3 trial, adding metformin to standard care in…

Cellular Modulators of the NRF2/KEAP1 Signaling Pathway in Prostate Cancer imrpress.com/journal/FBL/28… Prostate cancer, is typically treated with surgery, radiotherapy, and androgen-deprivation therapy (ADT) in advanced stages to slow disease progression. Emerging research…
Palazestrant, a novel oral Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), in patients with ER+/HER2− advanced or metastatic breast cancer: phase 1/2 study results …ast-cancer-research.biomedcentral.com/articles/10.11… Endocrine resistance remains a key hurdle…

Why attend #RENALC25, #BLADDR25 and #PROSCA25? Hear it straight from @Achard_Verane in this quick video 👇 ➡️ Register now: tinyurl.com/mryx8kwe 💎Dive into the clinical application of new GU oncology data 👥 Learn from multidisciplinary experts 🗓️3-6 December 2025 | 📍…
Disparities in receipt of palliative-intent treatment among disaggregated Hispanic populations with breast, lung, and #ProstateCancer in the United States🇺🇸 acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… Study reveals significant disparities in the receipt of palliative-intent interventions among…

Drs. Neal Shore and Alicia Morgans invite you to join for a short webinar discussing the highlights and implications for clinical practice of their recent publication on rPFS as a surrogate for OS in mHSPC patients 📰🧑⚕️ Register now & join on August 7th or on-demand thereafter!…
Molecular characterization of residual muscle-invasive bladder cancer identifies a scar-like transcriptomicprofile with favorable prognosis after neoadjuvant therapy aacrjournals.org/clincancerres/… This study investigates the prognostic significance of molecular profiling in residual…

HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis buff.ly/1loYQqK A comprehensive individual patient-level meta-analysis of over 2,500 patients from 11 studies demonstrated that the HER2DX genomic test…
ctDNA Detection in Cancer: A Comprehensive Overview of Current Detection Methods and Prospects academic.oup.com/oncolo/advance… Review explores the evolving role of circulating tumor DNA (ctDNA)🧬 as a minimally invasive biomarker in oncology, highlighting how different detection…

Out in @BCRJournal the results of a phase 1/2 trial testing palazestrant, a new endocrine therapy that retains a unique mechanism of action as CERAN (Complete Estrogen Receptor Antagonist) and SERD The phase 3 trial (OPERA-01) is ongoing @OncoAlert …ast-cancer-research.biomedcentral.com/articles/10.11…
Join us for the 10th Jubilee Edition of #BLADDR25! Register now: tinyurl.com/bdf4fw7y ➡️Get insights on the latest #BladderCancer data translated into clinical practice by @achoud72, @DrFelixGuerrero and many more!

News From Industry/ FLAURA2 Update Source AstraZeneca buff.ly/IxqmQjH Long-term follow-up from the Phase III FLAURA2 trial confirms that combining osimertinib with platinum-based chemotherapy and pemetrexed significantly improves overall survival in patients with…
Challenges in Defining Clinical Complete Response to Systemic Therapy in Muscle-invasive Bladder Cancer: Insights from the EORTC STARBURST Project euoncology.europeanurology.com/article/S2588-… The EORTC STARBURST-1 trial aims to refine treatment strategies for muscle-invasive bladder cancer by…

Early bird registration is OPEN! Don’t miss your chance to join the RENALC-BLADDR-PROSCA 2025 hybrid global forum on GU Oncology at a reduced rate. Secure your spot and get ready for an interactive learning experience with top experts. ➡️ Register now: tinyurl.com/bdf4fw7y…
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial buff.ly/A2GlREZ The final analysis of the TALAPRO-2 trial showed…
Molecular characterization of residual muscle-invasive bladder cancer identifies a scar-like transcriptomicprofile with favorable prognosis after neoadjuvant therapy aacrjournals.org/clincancerres/… This study analyzed RNA sequencing data from #BladderCancer patients treated with…

📌 HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis 🔗 thelancet.com/journals/lanon… ✨ HER2DX provides clinically meaningful prognostic stratification in early-stage HER2-positive breast cancer, beyond standard…
Clinical case discussion: Which treatment for this 62-year-old lady with HER2+ metastatic #BreastCancer❓ 🆓Registration here: tinyurl.com/edhvcb28 🧑💻Watch the discussion with @ElisaAgostinett and her colleagues @nicolobattisti, Véronique Diéras and Fatima Cardoso 🧑⚕️Get…
Early bird registration is OPEN! Don’t miss your chance to join the RENALC-BLADDR-PROSCA 2025 hybrid global forum on GU Oncology at a reduced rate. Secure your spot and get ready for an interactive learning experience with top experts. ➡️ Register now: tinyurl.com/bdf4fw7y…
